TAB METFORMIN

Small molecule

DDow University of Health Sciences

TAB METFORMIN is one of 6 small molecule programs targeting Hyperandrogenism. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperandrogenismActive, not recruiting

HyperandrogenismPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Hyperandrogenism

#DrugCompanyPhaseTrials

Lupron

AbbVie

Phase 2

1 2

Aldactone

Pfizer

Phase 1

1 3

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 1

1 4

Ethinyl Estradiol/norethindrone

AstraZeneca

Phase 2

1 5

Rhcg

UUniversity of Virginia

Phase 1

1 6

TAB METFORMIN

DDow University of Health Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperandrogenism1 trial

Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism

Unknown status·—·Phase 1/2·NCT03757923·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAB METFORMIN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAB METFORMIN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAB METFORMIN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dow University of Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: DDow University of Health Sciences

TAB METFORMIN

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperandrogenism1 trial

References

Drug Info

Quick Facts

Related News